Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,196.72 +15.98 (+0.31%) Dow
38,963.44 +111.17 (+0.29%) Nasdaq
16,382.07 +32.83 (+0.20%) Bitcoin USD
63,822.89 +509.65 (+0.80%) CMC Crypto 200
1,314.98 -50.14 (-3.67%)
Swedish Orphan Biovitrum AB (publ) (0MTD.IL)
- PR Newswire
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
- PR Newswire
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
- PR Newswire
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
